Drugs / 17ß-estradiol
last change Dec 2020 re-read 2 minutes ago

17ß-estradiol

English name 17β-estradiol
Developed for
essential hypertension · hypertensive disorder · vasomotor rhinitis
Investigated by
Bayer · Organon and Co · Solvay Pharmaceuticals

Trials 5 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00420342 Jan 2007 → Sep 2008 hypertensive disorder Bayer Completed No outcome recorded
Phase 33 trials
Phase 3 NCT01656434 Nov 2012 → Feb 2014 Organon and Co Terminated No outcome recorded
Phase 3 NCT00651599 Jul 2004 → May 2005 vasomotor rhinitis Bayer Completed No outcome recorded
Phase 3 NCT00102141 Apr 2004 → Jul 2005 essential hypertension Bayer Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00145522 Nov 2005 → Mar 2009 Solvay Pharmaceuticals Completed No outcome recorded
Also used as a comparator or background therapy in 3 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00537836 Comparator Oct 2007 → Dec 2008 vasomotor rhinitis Bayer Completed No outcome recorded
Phase not applicable2 trials
NCT04100655 Background Oct 2019 → Jun 2020 uterine disorder Sir Run Run Shaw Hospital Unknown No outcome recorded
NCT01418209 Comparator Nov 2011 → Jan 2013 Fred Hutchinson Cancer Center Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as 17-ß estradiol “NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.” NCT01656434
7

NCT04100655

NCT00537836

NCT01418209

NCT00145522

NCT00420342

NCT00102141

NCT00651599

Route Oral “given as tablets orally” NCT00102141